{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:59:43Z","timestamp":1761541183458},"reference-count":21,"publisher":"Georg Thieme Verlag KG","issue":"02","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2014]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Although some observational studies reported that the measured level of P2Y12-inhibition is predictive for thrombotic events, the clinical and economic benefit of incorporating PFT to personalize P2Y12-receptor directed antiplatelet treatment is unknown. Here, we assessed the clinical impact and cost-effectiveness of selecting P2Y12-inhibitors based on platelet function testing (PFT) in acute coronary syndrome (ACS) patients undergoing PCI. A decision model was developed to analyse the health economic effects of different strategies. PFT-guided treatment was compared with the three options of general clopidogrel, prasugrel or ticagrelor treatment. In the PFT arm, low responders to clopidogrel received prasugrel, while normal responders carried on with clopidogrel. The associated endpoints in the model were cardiovascular death, stent thrombosis and major bleeding. With a simulated cohort of 10,000 patients treated for one year, there were 93 less events in the PFT arm compared to general clopidogrel. In prasugrel and ticagrelor arms, 110 and 86 events were prevented compared to clopidogrel treatment, respectively. The total expected costs (including event costs, drug costs and PFT costs) for generic clopidogrel therapy were US$ 1,059\/patient. In the PFT arm, total costs were US$ 1,494, while in the prasugrel and ticagrelor branches they were US$ 3,102 and US$ 3,771, respectively. The incrementalcost- effectiveness-ratio (ICER) was US$ 46,770 for PFT-guided therapy, US$ 185,783 for prasugrel and US$ 315,360 for ticagrelor. In this model-based analysis, a PFT-guided therapy may have fewer adverse outcomes than general treatment with clopidogrel and may be more cost-effective than prasugrel or ticagrelor treatment in ACS patients undergoing PCI.<\/jats:p>","DOI":"10.1160\/th13-08-0679","type":"journal-article","created":{"date-parts":[[2013,10,24]],"date-time":"2013-10-24T08:57:36Z","timestamp":1382605056000},"page":"290-299","source":"Crossref","is-referenced-by-count":20,"title":["A model-based analysis of the clinical and economic impact of personalising P2Y12-receptor inhibition with platelet function testing in acute coronary syndrome patients"],"prefix":"10.1160","volume":"112","author":[{"given":"Niels","family":"Straub","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Beivers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekaterina","family":"Lenk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Aradi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Sibbing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2017,11,27]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehr236","article-title":"ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)","volume":"32","author":"CW Hamm","year":"2011","journal-title":"Eur Heart J"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","article-title":"ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)","volume":"33","author":"PG Steg","year":"2012","journal-title":"Eur Heart J"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"L Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"SD Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.jacc.2012.02.026","article-title":"A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents: Results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) Study","volume":"59","author":"D Trenk","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/jama.2011.290","article-title":"Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial","volume":"305","author":"MJ Price","year":"2011","journal-title":"J Am Med Assoc"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1056\/NEJMoa1209979","article-title":"Bedside monitoring to adjust antiplatelet therapy for coronary stenting","volume":"367","author":"JP Collet","year":"2012","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jacc.2010.03.048","article-title":"Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window","volume":"56","author":"D Sibbing","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.jacc.2010.04.047","article-title":"Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate","volume":"56","author":"L Bonello","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions","volume":"115","author":"DE Cutlip","year":"2007","journal-title":"Circulation"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0140-6736(09)62191-7","article-title":"Comparison of ticagrelor with clopi-dogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study","volume":"375","author":"CP Cannon","year":"2010","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ahj.2010.05.003","article-title":"Platelet response to clopidogrel and restenosis in patients treated predominantly with drug-eluting stents","volume":"160","author":"S Schulz","year":"2010","journal-title":"Am Heart J"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"A477.","DOI":"10.1016\/S0735-1097(13)61922-1","article-title":"Optimizing P2Y12-Receptor Inhibition in Acute Coronary Syndrome Patients after PCI Using Platelet Function Testing: Impact of Prasugrel versus High-Dose Clopidogrel","volume":"61","author":"D Aradi","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11239-012-0684-z","article-title":"Tailoring clopidogrel dose according to multiple electrode aggregometry decreases the rate of ischemic complications after percutaneous coronary intervention","volume":"34","author":"D Hazarbasanov","year":"2012","journal-title":"J Thromb Thrombolysis"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"251","DOI":"10.7326\/0003-4819-142-4-200502150-00007","article-title":"A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone","volume":"142","author":"MD Schleinitz","year":"2005","journal-title":"Ann Intern Med"},{"key":"ref23","first-page":"364","article-title":"Current clinical characteristics and economic impact of subacute stent thrombosis","volume":"14","author":"MR Reynolds","year":"2002","journal-title":"J Invasive Cardiol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1540-8183.2009.00431.x","article-title":"Determining the in-hospital cost of bleeding in patients undergoing percutaneous coronary intervention","volume":"22","author":"EF Ewen","year":"2009","journal-title":"J Interv Cardiol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1016\/j.jacc.2011.02.009","article-title":"2011 ACCF\/AHA focused update of the Guidelines for the Management of Patients with Unstable Angina\/Non-ST-Elevation Myocardial Infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons","volume":"57","author":"RS Wright","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1161\/CIRCULATIONAHA.109.900704","article-title":"Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38","volume":"121","author":"EM Mahoney","year":"2010","journal-title":"Circulation"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/eurheartj\/ehs149","article-title":"Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study","volume":"34","author":"E Nikolic","year":"2013","journal-title":"Eur Heart J"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1001\/archinternmed.2010.154","article-title":"Prasugrel as a potential cancer promoter: review of the unpublished data","volume":"170","author":"JS Floyd","year":"2010","journal-title":"Arch Intern Med"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1160\/TH13-08-0679.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T12:04:07Z","timestamp":1685534647000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1160\/TH13-08-0679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":21,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2017,11,21]]},"published-print":{"date-parts":[[2014,8]]}},"URL":"https:\/\/doi.org\/10.1160\/th13-08-0679","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}